James Bradner

Electra Therapeutics

Kathy Dong

Electra Therapeutics has appointed Kathy Dong as president and chief executive officer. Dong has over 15 years’ experience in corporate development, business operations, portfolio management and product commercialisation. She most recently served as chief operating Officer at Star Therapeutics, and previously held the position of vice president of commercial development at True North Therapeutics.

Memo Therapeutics

Erik van den Berg

Memo Therapeutics has appointed Erik van den Berg as chief executive officer. Berg brings more than two decades of industry experience to his new position. He currently serves as a board member for AM-Pharma, following his position as the company’s chief executive officer. Berg also currently serves as chairman for TargED Biopharmaceuticals, Tridek-One and Step Pharma.

OM Pharma

Roch Ogier

OM Pharma has appointed Roch Ogier as chief executive officer. Ogier brings a wealth of experience in the biotechnology field and across the healthcare sector to his new position. He most recently served as the company’s chief operating officer, following his position as chief business development officer. Prior to this, he served as a venture partner at Ataraxia Partners.

Sanofi

Brian Foard

Sanofi has appointed Brian Foard as head of its specialty care global business unit (GBU). Foard, who is also now a member of the company’s executive committee, has more than 20 years of specialty biopharma experience. He has most recently been serving as interim head of Sanofi’s GBU and head of specialty care North America and US country lead.

Cancer Research Horizons

Christoph Lengauer

Cancer Research Horizons has appointed Christoph Lengauer as chair of its therapeutic innovation board. Lengauer most recently co-founded Curie.Bio, a new model for venture capital in biotech for which he currently serves as chief scientific officer. He has also previously headed up drug discovery departments at Sanofi and Novartis, served as chief scientific officer of Blueprint Medicines and co-founded several other biotechs.

Cancer Research Horizons

Annalisa Jenkins

Cancer Research Horizons has appointed Annalisa Jenkins to its board of directors. Jenkins brings over 25 years of life sciences leadership expertise to the board, having held senior roles at Merck Serono and Bristol Myers Squibb. She was also previously president and chief executive officer of Dimension Therapeutics, is currently on the board of Genomics England and is a trustee at The King's Fund.

Pharmanovia

James Burt

Pharmanovia has appointed James Burt as chair of medicines for Europe's Value Added Medicines Sector Group. Burt brings over a decade of experience in senior positions to his new role and currently serves as chief executive officer for the company. Prior to this, he served as executive vice president, EMENA at Accord Healthcare, which followed on from his position as vice president, hospital business.

Johnson & Johnson

Eugene Woods

Johnson & Johnson has appointed Eugene Woods to its board of directors. Woods brings three decades of healthcare leadership experience to his new position. He currently serves as chief executive officer at Advocate Health. Woods also previously served as president and chief executive officer at Atrium Health. Prior to this, he was president and chief operating officer at CHRISTUS Health.